JAK2基因敲除HEK293细胞

JAK2基因敲除HEK293细胞
货号:

EDJ-KQ17828

物种:

细胞名称:

HEK293

基因名称:

JAK2

基因ID:

3717

规格:

1×10⁶cells

JAK2基因敲除细胞HEK293是由艾迪基因优化的CRISPR/Cas9编辑而成,采用Sanger测序法验证敲除,保证单克隆,活性良好。
货号 EDJ-KQ17828
产品名称 JAK2 Knockout HEK293 Cell Line
细胞 HEK293
Cellosaurus ID CVCL_0045
细胞别名 Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293
基因 JAK2
基因ID
基因别名 JTK10
摘要
This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
癌症类型 Non-tumor
细胞形态 Adherent
传代比率 1/2~1/4
完全培养基 DMEM + 10% FBS
冻存培养基 95%完全培养基+ 5% DMSO
* 仅供科研使用,不适用于人体或动物,包括临床、治疗或诊断用途。
Loci送检细胞STR信息
送检细胞名: HEK293
细胞库细胞STR信息
细胞库细胞名: HEK293
Allele1Allele2Allele1 Allele2
AmelogeninXX
CSF1P0121112
D2S13381919
D3S135815171517
D5S818889
D7S82011121112
D8S117912141214
D13S31712141214
D16S539913913
D18S5117181718
D19S43315181518
D21S112830.22830.2
FGA2323
Penta D910910
Penta E715715
TH0179.379.3
TPOX1111
vWA16191619
D6S10431111
D12S39119211115
D2S44111151115
* 该细胞系与收录于ATCC, DSMZ, JCRB 和 RIKEN数据库的细胞系STR数据匹配。
结论:该细胞 STR 鉴定正确。
* 研究用途免责声明:本内容基于公开的研究数据、生物信息学资源及计算分析生成,仅供研究参考。

相关研究文献

IF=11.9
Metabolism: clinical and experimental
Hepatic gluconeogenesis plays a crucial role in maintaining blood glucose homeostasis in mammals. Globe knockout of suppressor of cytokine signalling-2 (SOCS2), a feedback inhibitor of cytokine signalling, has been shown resistant to high-fat-diet (HFD)-induced hepatic steatosis with impaired glucose tolerance in mice. However, the underlying mechanism of SOCS2 regulates hepatic glucose homeostasis still undefined. In the present study, we demonstrated that the hepatic SOCS2 expression is markedly reduced in fasted C57BL/6 J mice or db/db mice. Moreover, hepatic SOCS2 expression levels are induced by metformin treatment. Ablation of SOCS2 attenuates suppressing effects of metformin on gluconeogenesis in hepatocytes. Gain- and loss-of-function studies indicated that SOCS2 regulates hepatic gluconeogenic genes expression and glucose output by mediating JAK2/STAT5 signalling pathway in db/db mice. Mechanistically, we observed that SOCS2 inactivates STAT5 by attenuating the interaction between JAK2 and STAT5, which in turn reduces hepatic gluconeogenesis. The present study reveals a critical role of SOCS2 in regulating hepatic gluconeogenesis. The inhibitory effect of metformin on gluconeogenesis is mediated, at least in part, by upregulating SOCS2 and therefore reducing hepatic gluconeogenic genes expression. SOCS2 may represent a new therapeutic target for the treatment of diabetes.
IF=6.6
Science signaling
Janus kinases (JAKs) bind to class I and II cytokine receptors, activating signaling and regulating gene transcription through signal transducer and activator of transcription (STAT) proteins. Type I interferons (IFNs) require the JAK members TYK2 and JAK1, which bind to the receptor subunits IFNAR1 and IFNAR2, respectively. We investigated the role of JAKs in regulating IFNAR signaling activity. Synthetic IFNARs in which the extracellular domains of IFNAR1 and IFNAR2 are replaced with nanobodies had near-native type I IFN signaling, whereas the homomeric variant of IFNAR2 initiated much weaker signaling, despite harboring docking sites for JAKs and STATs. Cells with JAK1 and TYK2 knockout (KO) showed residual signaling, suggesting partial complementation by the remaining JAKs, particularly when they were overexpressed. Live-cell micropatterning experiments confirmed the promiscuous binding of JAK1, JAK2, and TYK2 to IFNAR1 and IFNAR2, and their recruitment correlated with their relative cellular abundances. However, each JAK had a different efficacy in inducing cross-phosphorylation and downstream signaling. JAK binding was also promiscuous for other cytokine receptors, including IFN-L1, IL-10Rβ, TPOR, and GHR, but not for EPOR, which activated different downstream signaling pathways. These findings suggest that competitive binding of JAKs to cytokine receptors together with the varying absolute and relative abundances of the JAKs in different cell types can account for the cell type-dependent signaling pleiotropy of cytokine receptors.
该敲除模型可用于: - 研究JAK2在细胞因子受体信号和多效性中的作用。 - 研究JAK2缺失对信号效率和通路特异性的影响。 - 评估JAK2依赖性与非依赖性信号机制。 - 筛选在JAK2无效背景下靶向替代JAK家族成员的化合物。 - 在受体激活试验中验证JAK2的混杂性结合功能。

配套产品

相关产品

相关服务

基因敲除细胞基因敲除细胞
联系我们
*
*
*
来源:
service online

  • 留言
  • You can send email to contact us.
    邮箱
  • You can send email to contact us.
    电话
    联系电话
    中国总部
    18102225074(微信同号)

  •  回到顶部